Use of over-the-counter analgesics in patients with chronic liver disease: Physicians' recommendations

Drug Safety

Volumn 31, Issue 3, 2008, Pages 261-270

  Rossi, Simona ^a   Assis, David N ^a   Awsare, Monica ^a   Brunner, Mark ^b   Skole, Kevin ^c   Rai, Jitha ^d   Andrel, Jocelyn ^a   Herrine, Steven K ^a   Reddy, Rajender K ^d   Navarro, Victor J ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b GEISINGER HEALTH SYSTEM   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Analgesics, general; Cirrhosis; Hepatitis; Non prescription drugs; Nonsteroidal anti inflammatories, general; Paracetamol, general; Prescribing

Indexed keywords

NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ALCOHOL CONSUMPTION; ARTICLE; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL PRACTICE; DOSE LIVER FUNCTION RELATION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG SAFETY; GENERAL PRACTITIONER; HIGH RISK PATIENT; HUMAN; LIVER CIRRHOSIS; LIVER TOXICITY; MEDICAL SPECIALIST; PAIN; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 39749149553     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831030-00007     Document Type: Article

References (33)

1. 1. JF Westphal JM Brogard 1997 Drug administration in chronic liver disease Drug Saf 17 47 73 9258630 10.2165/00002018-199717010-00004 1:CAS:528:DyaK2sXls1Wisr0%3D Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Saf 1997; 17: 47–73
2. 2. TR Riley III AM Bhatti 2001 Preventive strategies in chronic liver disease: part I. Alcohol, vaccines, toxic medications and supplements, diet and exercise [published erratum appears in Am Fam Physician 2002; 65: 2438] Am Fam Physician 64 1555 60 11730310 Riley III TR, Bhatti AM. Preventive strategies in chronic liver disease: part I. Alcohol, vaccines, toxic medications and supplements, diet and exercise [published erratum appears in Am Fam Physician 2002; 65: 2438]. Am Fam Physician 2001; 64: 1555–60
3. 3. ED Ehrenpreis S Ehrenpreis 1998 Cytochrome P450: role in drug-induced hepatotoxicity Clin Liver Dis 2 457 70 10.1016/S1089-3261(05)70021-0 Ehrenpreis ED, Ehrenpreis S. Cytochrome P450: role in drug-induced hepatotoxicity. Clin Liver Dis 1998; 2: 457–70
4. 4. GD Benson 1983 Acetaminophen in chronic liver disease Clin Pharmacol Ther 33 95 101 6848304 10.1038/clpt.1983.14 1:STN:280:DyaL3s%2Fnsl2rsg%3D%3D Benson GD. Acetaminophen in chronic liver disease. Clin Pharmacol Ther 1983; 33: 95–101
5. 5. GC Farrell WG Cooksley LW Powell 1979 Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes Clin Pharmacol Ther 26 483 92 487696 1:CAS:528:DyaL3cXitVQ%3D Farrell GC, Cooksley WG, Powell LW. Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes. Clin Pharmacol Ther 1979; 26: 483–92
6. 6. EA Sotaniemi RO Pelkonen M Puukka 1980 Measurement of hepatic drug-metabolizing enzyme activity in man: comparison of three different assays Eur J Clin Pharmacol 17 267 74 6105079 10.1007/BF00625800 1:CAS:528:DyaL3cXktlOmu78%3D Sotaniemi EA, Pelkonen RO, Puukka M. Measurement of hepatic drug-metabolizing enzyme activity in man: comparison of three different assays. Eur J Clin Pharmacol 1980; 17: 267–74
7. 7. FP Guengerich CG Turvy 1991 Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples J Pharmacol Exp Ther 256 1189 94 2005581 1:CAS:528:DyaK3MXhvVehs70%3D Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991; 256: 1189–94
8. 8. HE Poulsen L Ranek PB Andreasen 1981 The hepatic glutathione content in liver diseases Scand J Clin Lab Invest 41 573 6 7336124 10.3109/00365518109090500 1:STN:280:DyaL387lt1Gjsw%3D%3D Poulsen HE, Ranek L, Andreasen PB. The hepatic glutathione content in liver diseases. Scand J Clin Lab Invest 1981; 41: 573–6
9. 9. CP Siegers KH Bossen M Younes 1982 Glutathione and glutathione-S-transferases in the normal and diseased human liver Pharmacol Res Commun 14 61 72 7071101 10.1016/S0031-6989(82)80052-0 1:CAS:528:DyaL38Xht1ShtL4%3D Siegers CP, Bossen KH, Younes M, et al. Glutathione and glutathione-S-transferases in the normal and diseased human liver. Pharmacol Res Commun 1982; 14: 61–72
10. 10. R Amman R Olsson 1978 Elimination of paracetamol in chronic liver disease Acta Hepatogastroenterol (Stuttg) 25 283 6 Amman R, Olsson R. Elimination of paracetamol in chronic liver disease. Acta Hepatogastroenterol (Stuttg) 1978; 25: 283–6 270
11. 11. RC Dart EK Kuffner BH Rumack 2000 Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review Am J Ther 7 123 34 11319580 10.1097/00045391-200007020-00009 1:STN:280:DC%2BD3MzitFKksQ%3D%3D Dart RC, Kuffner EK, Rumack BH. Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. Am J Ther 2000; 7: 123–34
12. 12. PB Watkins N Kaplowitz JT Slattery 2006 Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial JAMA 296 87 93 16820551 10.1001/jama.296.1.87 1:CAS:528:DC%2BD28Xms1KmsL0%3D Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296: 87–93
13. 13. JL Carson LR Willet 1993 Toxicity of nonsteroidal anti-inflammatory drugs: an overview of the epidemiological evidence Drugs 46 1 243 8 7506183 10.2165/00003495-199300461-00063 Carson JL, Willet LR. Toxicity of nonsteroidal anti-inflammatory drugs: an overview of the epidemiological evidence. Drugs 1993; 46 Suppl. 1: 243–8
14. 14. DC Brater SA Anderson D Brown-Cartwright 1986 Effects of nonsteroidal antiinflammatory drugs on renal function in patients with renal insufficiency and in cirrhotics Am J Kidney Dis 8 351 5 2947456 1:STN:280:DyaL2s%2FntlChuw%3D%3D Brater DC, Anderson SA, Brown-Cartwright D, et al. Effects of nonsteroidal antiinflammatory drugs on renal function in patients with renal insufficiency and in cirrhotics. Am J Kidney Dis 1986; 8: 351–5
15. 15. HJ Zimmerman 1998 Acetaminophen hepatotoxicity Clin Liver Dis 2 523 41 10.1016/S1089-3261(05)70025-8 Zimmerman HJ. Acetaminophen hepatotoxicity. Clin Liver Dis 1998; 2: 523–41
16. 16. AM Larson J Poison RJ Fontana 2005 Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study Hepatology 42 1364 72 16317692 10.1002/hep.20948 1:CAS:528:DC%2BD2MXhtlGns7rF Larson AM, Poison J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42: 1364–72
17. 17. PB Andreasen L Hutters 1979 Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver Acta Med Scand Suppl 624 99 105 284720 1:STN:280:DyaE1M7kt1Sgtw%3D%3D Andreasen PB, Hutters L. Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. Acta Med Scand Suppl 1979; 624: 99–105
18. 18. JA Forrest JA Clements LF Prescott 1982 Clinical pharmaco-kinetics of paracetamol Clin Pharmacokinet 7 93 107 7039926 10.2165/00003088-198207020-00001 1:STN:280:DyaL387mtlCmsA%3D%3D Forrest JA, Clements JA, Prescott LF. Clinical pharmaco-kinetics of paracetamol. Clin Pharmacokinet 1982; 7: 93–107
19. 19. GD Benson RS Koff KG Tolman 2005 The therapeutic use of acetaminophen in patients with liver disease Am J Ther 12 133 41 15767831 10.1097/01.mjt.0000140216.40700.95 Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther 2005; 12: 133–41
20. 20. J Claria JD Kent M Lopez-Parra 2005 Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites Hepatology 41 579 87 15723448 10.1002/hep.20595 1:CAS:528:DC%2BD2MXisFCrs78%3D Claria J, Kent JD, Lopez-Parra M, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 2005; 41: 579–87
21. 21. S Dargere T Collet D Crampon 2000 Lack of toxicity of acetaminophen in patients with chronic hepatitis C: a randomized controlled trial [abstract Gastroenterology 118 A947 Dargere S, Collet T, Crampon D, et al. Lack of toxicity of acetaminophen in patients with chronic hepatitis C: a randomized controlled trial [abstract]. Gastroenterology 2000; 118: A947
22. 22. EK Kuffner RC Dart GM Bogdan 2001 Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial Arch Intern Med 161 2247 52 11575982 10.1001/archinte.161.18.2247 1:CAS:528:DC%2BD3MXns1yrtbc%3D Kuffner EK, Dart RC, Bogdan GM, et al. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001; 161: 2247–52
23. 23. MH Leist LE Gluskin JA Payne 1985 Enhanced toxicity of acetaminophen in alcoholics: report of three cases J Clin Gastroenterol 7 55 9 3980965 10.1097/00004836-198502000-00008 1:STN:280:DyaL2M7lvVyjtw%3D%3D Leist MH, Gluskin LE, Payne JA. Enhanced toxicity of acetaminophen in alcoholics: report of three cases. J Clin Gastroenterol 1985; 7: 55–9
24. 24. HJ Zimmerman WC Maddrey 1995 Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure [published erratum appears in Hepatology 1995; 22: 1898] Hepatology 22 767 73 7657281 10.1002/hep.1840220312 1:CAS:528:DyaK2MXoslartbg%3D Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure [published erratum appears in Hepatology 1995; 22: 1898]. Hepatology 1995; 22: 767–73
25. 25. E Tanaka K Yamazaki S Misawa 2000 Update: the clinical importance of acetaminophen hepatotoxicity in non-alcoholic and alcoholic subjects J Clin Pharm Ther 25 325 32 11123483 10.1046/j.1365-2710.2000.00301.x 1:CAS:528:DC%2BD3MXktlWrsA%3D%3D Tanaka E, Yamazaki K, Misawa S. Update: the clinical importance of acetaminophen hepatotoxicity in non-alcoholic and alcoholic subjects. J Clin Pharm Ther 2000; 25: 325–32
26. 26. M Rabinovitz DH Thiel Van 1992 Hepatotoxicity of nonsteroidal anti-inflammatory drugs Am J Gastroenterol 87 1696 704 1449128 1:CAS:528:DyaK3sXptlKkuw%3D%3D Rabinovitz M, Van Thiel DH. Hepatotoxicity of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1992; 87: 1696–704
27. 27. P Gentilini 1993 Cirrhosis, renal function and NSAIDs J Hepatol 19 200 3 8301052 10.1016/S0168-8278(05)80571-9 1:STN:280:DyaK2c7jt1Ggsg%3D%3D Gentilini P. Cirrhosis, renal function and NSAIDs. J Hepatol 1993; 19: 200–3
28. 28. V Arroyo P Ginés A Rimola 1986 Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites: an overview with emphasis on pathogenesis Am J Med 81 104 22 2944381 10.1016/0002-9343(86)90912-5 1:CAS:528:DyaL28Xls12rtr8%3D Arroyo V, Ginés P, Rimola A, et al. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites: an overview with emphasis on pathogenesis. Am J Med 1986; 81: 104–22
29. 29. RM Pérez-Ayuso V Arroyo J Camps 1984 Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis Kidney Int 26 72 80 6434791 10.1038/ki.1984.136 Pérez-Ayuso RM, Arroyo V, Camps J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984; 26: 72–80
30. 30. M López-Parra J Claria A Planaguma 2002 Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites Br J Pharmacol 135 891 900 11861316 10.1038/sj.bjp.0704528 López-Parra M, Claria J, Planaguma A, et al. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol 2002; 135: 891–900
31. 31. DC Brater SA Anderson D Brown-Cartwright 1987 Reversible acute decrease in renal function by NSAIDs in cirrhosis Am J Med Sci 294 168 74 3661615 10.1097/00000441-198709000-00007 1:STN:280:DyaL1c%2FitFWgsQ%3D%3D Brater DC, Anderson SA, Brown-Cartwright D. Reversible acute decrease in renal function by NSAIDs in cirrhosis. Am J Med Sci 1987; 294: 168–74
32. 32. LA Garcia Rodriguez R Williams LE Derby 1994 Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors Arch Intern Med 154 311 6 8297198 10.1001/archinte.154.3.311 1:STN:280:DyaK2c7isl2isQ%3D%3D Garcia Rodriguez LA, Williams R, Derby LE, et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154: 311–6
33. 33. JE Biskupiak DI Brixner K Howard 2006 Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs J Pain Palliat Care Pharmacother 20 7 14 16931473 10.1080/J354v20n03_03 Biskupiak JE, Brixner DI, Howard K, et al. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J Pain Palliat Care Pharmacother 2006; 20: 7–14